Of note, there were significant differences in the response rates among the KRAS/STK11 (KL) (7.4%) vs. KRAS (28.6%) NSCLC subgroups (p < 0.001) in the Stand Up To Cancer (SU2C) cohort (primarily nivolumab treatment) and patients treated with nivolumab in the phase III CheckMate-057 (RR: KL 0% vs. KRAS 18.2%, p = 0.04) [13]. The gene discussed is KRAS; the disease is cancer.